ARN2966

ARN2966 is a potent post-transcriptional modulator of APP expression; reduces expression of APP with resultant lower production of Aβ. IC50 value: Target: AβThis potent post-transcriptional modulation of APP expression differs from other mechanisms such as inhibition of secretases. Secretase inhibitors have been pursued as disease modifying strategies by a number of pharmaceutical firms but they have encountered numerous setbacks during clinical development. ARN2966 is non toxic, orally absorbable, blood-brain-barrier penetrable, and effective in vitro and in vivo.

Signaling Pathways >> Neuronal Signaling >> Amyloid-β

Research Areas >> Neurological Disease

[1]. http://arianeurosciences.com/science.html

FPS-ZM1 | Amyloid β-Protein (25-35) trifluoroacetate salt | Ginsenoside Rg3 | Geniposide | Ginsenoside Rg1 | β-Amyloid-42 | Semagacestat(LY450139) | Edonerpic maleate | Notoginsenoside R1 | Latrepirdine | Frentizole | Ginsenoside Re | Ginsenoside Rg2